Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

US8946446B2 · kind B2 · utility

Assignee

• PHENEX PHARMACEUTICALS AG · DE

Inventors

• Christoph Steeneck · Dossenheim, DE
• Olaf Kinzel · Heidelberg, DE
• Christian Gege · Ehingen (Donau), DE
• Gerald Kleymann · Bad Salzuflen, DE
• Thomas Hoffmann · Santa Cruz, US

Key dates

• Filing date: Apr 13, 2012
• Grant date: Feb 3, 2015
• Expiry date: Apr 13, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/10
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.